<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Publications Archive - Scholar Rock</title>
	<atom:link href="https://scholarrock.com/publications/feed/" rel="self" type="application/rss+xml" />
	<link>https://scholarrock.com/publications/</link>
	<description></description>
	<lastBuildDate>Mon, 22 Jul 2024 14:31:28 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.7.1</generator>

<image>
	<url>https://scholarrock.com/wp-content/uploads/2020/08/cropped-favicon-32x32.png</url>
	<title>Publications Archive - Scholar Rock</title>
	<link>https://scholarrock.com/publications/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study</title>
		<link>https://scholarrock.com/publications/long-term-efficacy-safety-and-patient-reported-outcomes-of-apitegromab-in-patients-with-spinal-muscular-atrophy-results-from-the-36-month-topaz-study/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Mon, 22 Jul 2024 14:31:27 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=publication&#038;p=1188</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/publications/long-term-efficacy-safety-and-patient-reported-outcomes-of-apitegromab-in-patients-with-spinal-muscular-atrophy-results-from-the-36-month-topaz-study/">Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/publications/long-term-efficacy-safety-and-patient-reported-outcomes-of-apitegromab-in-patients-with-spinal-muscular-atrophy-results-from-the-36-month-topaz-study/">Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis</title>
		<link>https://scholarrock.com/publications/an-antibody-that-inhibits-tgf-%ce%b21-release-from-latent-extracellular-matrix-complexes-attenuates-the-progression-of-renal-fibrosis/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Tue, 09 Jul 2024 13:27:32 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=publication&#038;p=1187</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/publications/an-antibody-that-inhibits-tgf-%ce%b21-release-from-latent-extracellular-matrix-complexes-attenuates-the-progression-of-renal-fibrosis/">An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/publications/an-antibody-that-inhibits-tgf-%ce%b21-release-from-latent-extracellular-matrix-complexes-attenuates-the-progression-of-renal-fibrosis/">An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3</title>
		<link>https://scholarrock.com/publications/safety-and-efficacy-of-apitegromab-in-patients-with-spinal-muscular-atrophy-types-2-and-3/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Fri, 09 Feb 2024 22:21:17 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=publication&#038;p=1161</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/publications/safety-and-efficacy-of-apitegromab-in-patients-with-spinal-muscular-atrophy-types-2-and-3/">Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/publications/safety-and-efficacy-of-apitegromab-in-patients-with-spinal-muscular-atrophy-types-2-and-3/">Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease</title>
		<link>https://scholarrock.com/publications/preclinical-safety-assessment-and-toxicokinetics-of-apitegromab-an-antibody-targeting-proforms-of-myostatin-for-the-treatment-of-muscle-atrophying-disease/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Wed, 14 Jul 2021 17:54:25 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=publication&#038;p=1005</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/publications/preclinical-safety-assessment-and-toxicokinetics-of-apitegromab-an-antibody-targeting-proforms-of-myostatin-for-the-treatment-of-muscle-atrophying-disease/">Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/publications/preclinical-safety-assessment-and-toxicokinetics-of-apitegromab-an-antibody-targeting-proforms-of-myostatin-for-the-treatment-of-muscle-atrophying-disease/">Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy</title>
		<link>https://scholarrock.com/publications/a-randomized-phase-1-safety-pharmacokinetic-and-pharmacodynamic-study-of-the-novel-myostatin-inhibitor-apitegromab-srk-015-a-potential-treatment-for-spinal-muscular-atrophy/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Tue, 11 May 2021 19:20:48 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=publication&#038;p=989</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/publications/a-randomized-phase-1-safety-pharmacokinetic-and-pharmacodynamic-study-of-the-novel-myostatin-inhibitor-apitegromab-srk-015-a-potential-treatment-for-spinal-muscular-atrophy/">A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/publications/a-randomized-phase-1-safety-pharmacokinetic-and-pharmacodynamic-study-of-the-novel-myostatin-inhibitor-apitegromab-srk-015-a-potential-treatment-for-spinal-muscular-atrophy/">A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors</title>
		<link>https://scholarrock.com/publications/nonclinical-development-of-srk-181-an-anti-latent-tgf%ce%b21-monoclonal-antibody-for-the-treatment-of-locally-advanced-or-metastatic-solid-tumors/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Mon, 22 Mar 2021 20:17:38 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock.com/?post_type=publication&#038;p=976</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/publications/nonclinical-development-of-srk-181-an-anti-latent-tgf%ce%b21-monoclonal-antibody-for-the-treatment-of-locally-advanced-or-metastatic-solid-tumors/">Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/publications/nonclinical-development-of-srk-181-an-anti-latent-tgf%ce%b21-monoclonal-antibody-for-the-treatment-of-locally-advanced-or-metastatic-solid-tumors/">Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015</title>
		<link>https://scholarrock.com/publications/structural-basis-of-specific-inhibition-of-extracellular-activation-of-pro-or-latent-myostatin-by-the-monoclonal-antibody-srk-015/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Fri, 17 Apr 2020 15:24:07 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock301.wpengine.com/?post_type=publication&#038;p=666</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/publications/structural-basis-of-specific-inhibition-of-extracellular-activation-of-pro-or-latent-myostatin-by-the-monoclonal-antibody-srk-015/">Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/publications/structural-basis-of-specific-inhibition-of-extracellular-activation-of-pro-or-latent-myostatin-by-the-monoclonal-antibody-srk-015/">Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Selective inhibition of TGFB1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape</title>
		<link>https://scholarrock.com/publications/selective-inhibition-of-tgfb1-activation-overcomes-primary-resistance-to-checkpoint-blockade-therapy-by-altering-tumor-immune-landscape/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Wed, 25 Mar 2020 15:24:58 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock301.wpengine.com/?post_type=publication&#038;p=667</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/publications/selective-inhibition-of-tgfb1-activation-overcomes-primary-resistance-to-checkpoint-blockade-therapy-by-altering-tumor-immune-landscape/">Selective inhibition of TGFB1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/publications/selective-inhibition-of-tgfb1-activation-overcomes-primary-resistance-to-checkpoint-blockade-therapy-by-altering-tumor-immune-landscape/">Selective inhibition of TGFB1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation</title>
		<link>https://scholarrock.com/publications/a-sensitive-and-selective-immunoassay-for-the-quantitation-of-serum-latent-myostatin-after-in-vivo-administration-of-srk-015-a-selective-inhibitor-of-myostatin-activation/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Fri, 26 Jul 2019 15:25:34 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock301.wpengine.com/?post_type=publication&#038;p=668</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/publications/a-sensitive-and-selective-immunoassay-for-the-quantitation-of-serum-latent-myostatin-after-in-vivo-administration-of-srk-015-a-selective-inhibitor-of-myostatin-activation/">A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/publications/a-sensitive-and-selective-immunoassay-for-the-quantitation-of-serum-latent-myostatin-after-in-vivo-administration-of-srk-015-a-selective-inhibitor-of-myostatin-activation/">A Sensitive and Selective Immunoassay for the Quantitation of Serum Latent Myostatin after In Vivo Administration of SRK-015, a Selective Inhibitor of Myostatin Activation</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Specific Inhibition of Myostatin Activation is Beneficial in Mouse Models of SMA Therapy</title>
		<link>https://scholarrock.com/publications/specific-inhibition-of-myostatin-activation-is-beneficial-in-mouse-models-of-sma-therapy/</link>
		
		<dc:creator><![CDATA[rbracey]]></dc:creator>
		<pubDate>Mon, 01 Apr 2019 15:30:43 +0000</pubDate>
				<guid isPermaLink="false">https://scholarrock301.wpengine.com/?post_type=publication&#038;p=669</guid>

					<description><![CDATA[<p>The post <a href="https://scholarrock.com/publications/specific-inhibition-of-myostatin-activation-is-beneficial-in-mouse-models-of-sma-therapy/">Specific Inhibition of Myostatin Activation is Beneficial in Mouse Models of SMA Therapy</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The post <a href="https://scholarrock.com/publications/specific-inhibition-of-myostatin-activation-is-beneficial-in-mouse-models-of-sma-therapy/">Specific Inhibition of Myostatin Activation is Beneficial in Mouse Models of SMA Therapy</a> appeared first on <a href="https://scholarrock.com">Scholar Rock</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
